Denali Therapeutics (DNLI) EBITDA (2017 - 2026)

Denali Therapeutics (DNLI) has reported EBITDA for 10 consecutive years, with -$137.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA rose 5.65% year-over-year to -$137.4 million; the TTM figure through Mar 2026 stood at -$547.1 million (down 6.19% YoY), while the FY2025 annual figure was -$555.3 million, down 13.95% from the prior year.
• EBITDA was little changed at -$137.4 million in Q1 2026 per DNLI's latest filing, from -$137.4 million in the prior quarter.
• Across five years, EBITDA topped out at $170.5 million in Q2 2023 and bottomed at -$145.6 million in Q1 2025.
• Historically, EBITDA has averaged -$101.0 million across 5 years, with a median of -$120.8 million in 2023.
• Annual changes were most pronounced in 2023 — EBITDA jumped 377.59% — and 2024, when it slumped 168.39%.
• Denali Therapeutics' EBITDA stood at -$105.3 million in 2022, then decreased by 25.85% to -$132.6 million in 2023, then grew by 2.06% to -$129.8 million in 2024, then fell by 5.79% to -$137.4 million in 2025, then climbed by 0.01% to -$137.4 million in 2026.
• Business Quant data shows DNLI's EBITDA at -$137.4 million in Q1 2026, -$137.4 million in Q4 2025, and -$137.4 million in Q3 2025.